MeMed Diagnostics

At MeMed, a leader in host response technologies, we decode the body’s complex signals into simple insights that improve people’s lives. By leveraging our expertise in host-response profiling and machine-learning algorithms, we are creating a portfolio of tests that address tough clinical dilemmas. Importantly, with the support of public and private partnerships, we have developed a point-of-need, rapid measurement platform called MeMed Key® to ensure timely availability of these novel tests during the clinician’s decision-making workflow.

Our lead product, MeMed BV®, accurately differentiates bacterial from viral infection, enabling improved patient management, including appropriate antibiotic use, helping address the global healthcare challenge of antimicrobial resistance. Based on computational integration of bacterial and viral-responsive immune proteins, Key delivers the BV result in 15 minutes from serum; this test was clinically validated on thousands of patients, is CE-marked and FDA cleared.

Another pivotal question that the clinician considers during the fever encounter is will this patient deteriorate? Accordingly, to meet the urgent need during the ongoing pandemic of risk stratifying COVID-19 patients, we are developing MeMed COVID-19 Severity™. Also run on MeMed Key in 15 minutes and the focus of this prize application, this new tool provides a score predicting the likelihood of a severe outcome and if care escalation should be considered.

MeMed’s headquarters are in Israel, with a subsidiary in the US. MeMed’s international team exemplifies bio-convergence, encompassing experts in molecular immunology, bioinformatics, assay development, engineering, and infectious disease. Currently, commercial, sales and service divisions are being expanded to support launch.